This federal Project Grant award of $2,332,500.00, provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to develop a novel model of a prison learning health system to address disparities in HIV treatment, HIV prevention, and substance use disorder (SUD) treatment among incarcerated individuals. The key objectives of this project, which will be embedded in Washington's state prisons, are to: 1) build the foundation for a...
This Project Grant award of $1,192,612 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to integrate HIV prevention services into clinical care settings for people with opioid use disorder (OUD). The project will: Conduct a systematic assessment of healthcare utilization, HIV prevention services, and medication for OUD (MOUD) using claims and emergency department data; Use an evidence-based quality improvement (EBQI) process...
This Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) provides $322,302 to Yale University over 5 years to support the development of an independent researcher focused on implementing culturally appropriate HIV prevention interventions that target criminal justice populations. The key products and services to be delivered under this award include: Formal coursework, seminars, interdisciplinary mentorship, and...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), provides $2,314,854 to the University of Rhode Island to evaluate the spillover effects of HIV interventions among marginalized populations that use illicit substances. The project will leverage existing network study data from Chicago to develop new methodological approaches for assessing spillover in sociometric network-based studies, addressing...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $239,148 to the Regents of the University of Minnesota to develop and pilot a telehealth intervention delivered through syringe service programs (SSPs) to improve uptake and retention of pre-exposure prophylaxis (PrEP) and medication for opioid use disorder (MOUD) among people who inject drugs (PWID). The 3-year project (9/15/2024 - 7/31/2027) will...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to increase HIV and substance use prevention and treatment among adolescent and young adult (AYA) survivors of sexual violence. The $672,206 grant, awarded on June 15, 2025, will support the following key objectives: Tailor existing Sexual Assault Nurse Examiner (SANE) services to incorporate same-day HIV prophylaxis and substance use prevention,...
This Project Grant award for $1,551,042 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will establish a Regional Research Hub (RRH) in metropolitan Atlanta, Georgia to improve linkages to care for recently incarcerated individuals with substance use disorder (SUD) and HIV status-neutral populations. The key aims of the project are to: 1) pilot test an intervention called SUCCESS-E to link persons with SUD in the Fulton County...
The National Institute on Drug Abuse (NIDA) awarded a $1,334,540 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to The University of Kentucky Research Foundation. The grant funds a 5-year project to optimize the delivery of pre-exposure prophylaxis (PrEP) care for people who inject drugs (PWID) in rural Kentucky. The project will deploy adaptive intervention strategies, including peer-led case management and mobile outreach, across three rural syringe service...
This Project Grant award from the National Institutes of Health (NIH) Office of the Director (CFDA 93.310 - Trans-NIH Research Support) provides $1,566,226 to Research Triangle Institute (RTI International) to evaluate the effectiveness and implementation of a couples-based shared decision-making intervention called CUPID. The intervention aims to improve uptake, persistence, and adherence to biomedical HIV pre-exposure prophylaxis (PrEP) options among women in Uganda by engaging male partners...
This $677,589 Project Grant award from the National Institutes of Health (NIH) Office of the Director's Trans-NIH Research Support program (CFDA 93.310) supports the development and pilot testing of a novel HIV prevention program targeting women experiencing incarceration. The "FIT for PrEP" (F4P) program aims to link these high-risk women to post-release pre-exposure prophylaxis (PrEP) services and address associated social determinants of health during community re-entry. Key aspects...
STOP (SHARED DECISION MAKING TO TREAT OR PREVENT) HIV IN JUSTICE POPULATIONS - PROJECT SUMMARY/ABSTRACT THE U.S. ENDING THE HIV EPIDEMIC (EHE) PLAN AIMS TO REDUCE NEW HIV INFECTIONS BY 90% BY 2030 THROUGH PROVIDING PRE-EXPOSURE PROPHYLAXIS (PREP) FOR THOSE AT RISK FOR HIV AND ANTIRETROVIRAL THERAPY (ART) FOR THOSE WITH HIV. THE EHE DOES NOT INTEGRATE SUBSTANCE USE DISORDER (SUD) ASSESSMENTS AND TREATMENTS NOR PROVIDE IMPLEMENTATION STRATEGIES ON PROVIDING PREP/ART FOR PERSONS WHO USE DRUGS (PWUD) INVOLVED IN THE JUSTICE SYSTEM, A CRITICALLY UNDERSERVED POPULATION. IN RESPONSE TO RFA-DA-24: ENDING THE HIV EPIDEMIC: FOCUS ON JUSTICE POPULATIONS WITH SUD (R61/R33), OUR PROPOSED STUDY TITLED STOP (SHARED DECISION MAKING TO TREAT OR PREVENT) HIV IN JUSTICE POPULATIONS IS A 5-YEAR PROJECT; THE FIRST YEAR (R61) IS DEDICATED TO A SINGLE SITE PILOT STUDY IN CT, FOLLOWED BY A 4-YEAR, 4 SITE (CT, KY, AND 2 IN TX) TYPE 3 HYBRID IMPLEMENTATION-EFFECTIVENESS STUDY (R33). WE BUILD ON EXISTING PARTNERSHIPS BETWEEN OUR MULTI-DISCIPLINARY RESEARCH TEAMS, JUSTICE AND COMMUNITY AGENCIES, AND STAKEHOLDERS WITH LIVED EXPERIENCE, TO DEVELOP AND ASSESS A PATIENT-CENTERED APPROACH TO ACCESS PREP/ART/SUD SERVICES. FOLLOWING A DIFFERENTIATED SERVICE DELIVERY MODEL IMPLEMENTATION APPROACH, WE FOCUS ON INCORPORATING (1) RISK ASSESSMENTS CONDUCTED BY PATIENT NAVIGATORS (PN) AND (2) PROVIDING PATIENT CHOICE (PC) OPTIONS FOR SERVICES DELIVERY METHODS (E.G., BRICK AND MORTAR CLINIC, TELEHEALTH, MOBILE HEALTH UNIT) TO ACCESS PREP/ART/SUD; THIS ENHANCED IMPLEMENTATION APPROACH WILL BE COMPARED TO ROUTINE PN ALONE AND INCLUDE IMPLEMENTATION AND PARTICIPANT OUTCOMES. AIM 1 (R61) IS TO DEVELOP AND PILOT TEST THE PN+PC MENU OF OPTIONS OF PREP/ART AND SUD TREATMENT SERVICES FOR JUSTICE-INVOLVED PWUD COMPARED TO ESTABLISHED PN IN CT, WHICH WILL BE ACHIEVED BY MEETING THE FOLLOWING MILESTONES: (1) BUILD UPON ESTABLISHED COLLABORATIONS TO INCLUDE MULTIPLE SERVICE DELIVERY MODELS AND THE PERSPECTIVES OF PERSONS WITH LIVED EXPERIENCE; (2) CURATE A MENU OF PC OPTIONS TO ACCESS PREP/ART AND SUD SERVICES; (3) CONDUCT A PILOT STUDY THAT INCLUDES AMONG N=30 ADULTS WITH RECENT JUSTICE SYSTEM INVOLVEMENT WITH DSM-5 SUD AT RISK OR LIVING WITH HIV, RANDOMIZED 1:1 TO PN VS. PN+PC TO ASSESS ACCEPTABILITY, FEASIBILITY, AND PROPORTION WHO (A) ACCESS A CLINICIAN AND (B) RECEIVE TREATMENT (ART, PREP, SUD, HARM REDUCTION); (4) SEEK GUIDANCE FROM THE PATIENT ENGAGEMENT RESOURCE CENTER TO INFORM THE FINAL IMPLEMENTATION MODEL OF THE R33; (5) DEVELOP A COMMON SET OF R33 MEASURES; AND (6) OBTAIN R33 IRB/OHRP APPROVAL. AIM 2 (R33) WILL USE R61 DATA TO INFORM OUR TYPE 3 HYBRID IMPLEMENTATION-EFFECTIVENESS STUDY OF PN VS PN+PC IN 4 COMMUNITIES (CT, 2 IN TX, KY) USING THE R61 ELIGIBILITY CRITERIA, WITH AIM 2. 1 EVALUATING PATIENT- LEVEL OUTCOMES (PROPORTION ACCESSING CLINICIANS AND TREATMENT) AND AIM 2.2 ASSESSING SYSTEM-LEVEL IMPLEMENTATION OUTCOMES (ACCEPTABILITY, ADOPTION, PENETRATION), SUSTAINMENT, AND COSTS OF IMPLEMENTING BOTH PN AND PN+PC APPROACHES. THIS STUDY HAS THE POTENTIAL TO BE PARADIGM-SHIFTING BY ASSESSING HOW BEST TO ENGAGE A POPULATION WHO STRUGGLES TO ACCESS THE TRADITIONAL HEALTH SYSTEM AND DETERMINING IF A CHOICE IN HOW THEY ENGAGE HIV/SUD SERVICES IMPACTS CLINICAL AND SYSTEM-LEVEL OUTCOMES.